- Home
- NERV vs SNAL Comparison
NERV vs SNAL Comparison
Compare NERV & SNAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NERV | SNAL |
|---|---|---|
| Founded | 2007 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.2M | 33.2M |
| IPO Year | 2014 | 2022 |
Fundamental Metrics
Financial Performance| Metric | NERV | SNAL |
|---|---|---|
| Price | $3.97 | $0.88 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 40.4K | 29.2K |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $82,330,445.00 |
| Revenue This Year | N/A | $13.87 |
| Revenue Next Year | N/A | $26.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.15 | $0.64 |
| 52 Week High | $12.46 | $3.42 |
Technical Indicators
Market Signals| Indicator | NERV | SNAL |
|---|---|---|
| Relative Strength Index (RSI) | 51.62 | 44.87 |
| Support Level | $3.70 | $0.86 |
| Resistance Level | $4.07 | $0.95 |
| Average True Range (ATR) | 0.29 | 0.07 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 62.37 | 16.67 |
Price Performance
Historical ComparisonAbout NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About SNAL Snail Inc.
Snail Inc is an independent developer and publisher of interactive digital entertainment for consumers around the world, with a portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States.